Psyence Biomedical Ltd. (PBM) Balance Sheet
PBM balance sheet, FY2026
March 31, 2026 · U.S. dollars$17.6M assets = $623,190 liabilities + $16.9M equity
Both columns are drawn to the same scale: what PBM owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PBM financial health
Descriptive bands, not a rating. Fiscal FY2026.
PBM balance sheet trends, FY2024–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.1MFY2024 | $17.6MFY2026 | +293.9%/yr | |
| Total liabilities | $12.1MFY2024 | $623,190FY2026 | −77.3%/yr | |
| Shareholders’ equity | −$11.0MFY2024 | $16.9MFY2026 | — | |
| Cash & short-term investments | $762,799FY2024 | $7.4MFY2026 | +212.4%/yr | |
| Working capital | −$11.0MFY2024 | $8.5MFY2026 | +$19.5M |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PBM assets
PBM liabilities and equity
PBM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PBM balance sheet
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $7.4M | $6.1M | $762,799 |
| Cash & equivalents | $7.4M | $6.1M | $762,799 |
| Short-term investments | — | — | −$29,611 |
| Receivables | $362,764 | $137,348 | $41,747 |
| Inventory | $0 | $0 | −$29,611 |
| Other current assets | $1.3M | $287,760 | $351,737 |
| Total current assets | $9.1M | $6.6M | $1.1M |
| Property, plant & equipment (net) | $6,059 | $11,096 | $5,487 |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $8.5M | $745,000 | $0 |
| Other non-current assets | $0 | $0 | $0 |
| Total assets | $17.6M | $7.3M | $1.1M |
| Liabilities | |||
| Accounts payable | $229,509 | $261,937 | $562,352 |
| Short-term debt | — | — | $10.4M |
| Deferred revenue | — | — | −$562,352 |
| Total current liabilities | $623,190 | $594,366 | $12.1M |
| Long-term debt | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 |
| Total liabilities | $623,190 | $594,366 | $12.1M |
| Shareholders' equity | |||
| Common stock & paid-in capital | $78.7M | $61.8M | $46.1M |
| Retained earnings (deficit) | −$63.4M | −$56.4M | −$57.5M |
| Accumulated other comprehensive income | $396,177 | $351,198 | $361,057 |
| Total shareholders' equity | $16.9M | $6.7M | −$11.0M |
| Key figures | |||
| Total debt | — | — | $10.4M |
| Net cash (debt) | — | — | −$9.7M |
| Working capital | $8.5M | $6.0M | −$11.0M |
| Tangible book value | $16.9M | $6.7M | −$11.0M |
| Book value per share | — | — | −$1.68 |
| Shares outstanding | — | — | 6.5M |
| Current ratio | 14.62 | 11.04 | 0.09 |
| Quick ratio | 12.53 | 10.55 | 0.07 |
| Equity / assets | 96.5% | 91.9% | −969.2% |
| Sep '25 | Dec '24 | Sep '24 | Dec '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & short-term investments | $7.2M | $1.9M | $1.9M | $733 | $9,802 | $15,956 | $172,895 | $214,936 | $306,875 | $431,905 | $648,282 |
| Cash & equivalents | $7.2M | $1.9M | $1.9M | $733 | $9,802 | $15,956 | $128,677 | $214,936 | $306,875 | $431,905 | $648,282 |
| Receivables | $174,187 | $125,080 | $0 | $0 | $67,181 | $60,898 | $1.1M | $0 | $0 | $39,546 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1 | $1 | $0 | $0 | −$39,546 | $0 |
| Other current assets | $258,092 | $185,773 | $310,853 | $393 | $104,411 | $211,743 | $333,526 | $325,990 | $345,667 | $365,291 | $324,938 |
| Total current assets | $7.6M | $2.2M | $2.2M | $1,126 | $181,394 | $288,598 | $1.6M | $540,926 | $652,542 | $797,196 | $973,220 |
| Property, plant & equipment (net) | $8,690 | $10,126 | $10,126 | $5 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $5.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $1 | $16.5M | $16.1M | $257.3M | $255.9M | $255.2M | $255.2M | $255.3M |
| Total assets | $12.8M | $2.3M | $2.3M | $1,132 | $16.7M | $16.4M | $258.9M | $256.5M | $255.9M | $256.0M | $256.2M |
| Liabilities | |||||||||||
| Accounts payable | $235,868 | $805,613 | $805,613 | $562 | — | $1.6M | $2,187 | — | — | $36,888 | — |
| Short-term debt | — | $2.5M | — | $10,447 | $1.2M | $685,000 | — | — | — | — | — |
| Deferred revenue | — | — | — | $126 | — | — | — | — | — | — | — |
| Total current liabilities | $943,068 | $3.5M | $3.5M | $12,104 | $15.3M | $14.9M | $14.3M | $187,040 | $213,704 | $142,674 | $68,702 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13.9M | $14.0M | $16.2M | $19.5M |
| Total liabilities | $943,068 | $3.5M | $3.5M | $12,104 | $15.3M | $14.9M | $14.3M | $14.1M | $14.2M | $16.4M | $19.6M |
| Shareholders' equity | |||||||||||
| Common stock & paid-in capital | $68.9M | $52.9M | — | $46,125 | $16.6M | $16.2M | $258.6M | $255.9M | $255.0M | $255.0M | $255.0M |
| Retained earnings (deficit) | −$58.4M | −$54.5M | −$54.5M | −$57,458 | −$15.2M | −$14.7M | −$13.9M | −$13.5M | −$13.4M | −$15.4M | −$18.4M |
| Accumulated other comprehensive income | $1.4M | $260,017 | — | $361 | — | — | — | — | — | — | — |
| Total shareholders' equity | $11.9M | −$1.3M | −$1.3M | −$10,972 | $1.5M | $1.5M | $244.7M | $242.4M | $241.6M | $239.6M | $236.6M |
| Key figures | |||||||||||
| Total debt | — | $2.5M | — | $10,447 | $1.2M | $685,000 | — | — | — | — | — |
| Net cash (debt) | — | −$568,343 | — | −$9,714 | −$1.2M | −$669,044 | — | — | — | — | — |
| Working capital | $6.7M | −$1.3M | −$1.3M | −$10,978 | −$15.1M | −$14.6M | −$12.7M | $353,886 | $438,838 | $654,522 | $904,518 |
| Tangible book value | $11.9M | −$1.3M | −$1.3M | −$10,972 | $1.5M | $1.5M | $244.7M | $242.4M | $241.6M | $239.6M | $236.6M |
| Book value per share | $8.01 | — | — | −$0.00 | $0.18 | $0.13 | — | — | — | — | — |
| Shares outstanding | 1.5M | — | — | 13.4M | 8.0M | 11.4M | — | — | — | — | — |
| Current ratio | 8.09 | 0.64 | 0.64 | 0.09 | 0.01 | 0.02 | 0.11 | 2.89 | 3.05 | 5.59 | 14.17 |
| Quick ratio | 7.82 | 0.59 | 0.55 | 0.06 | 0.01 | 0.01 | 0.09 | 1.15 | 1.44 | 3.30 | 9.44 |
| Debt / equity | — | — | — | — | 0.81 | 0.45 | — | — | — | — | — |
| Equity / assets | 92.6% | −55.7% | −55.7% | −969.3% | 8.7% | 9.3% | 94.5% | 94.5% | 94.4% | 93.6% | 92.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed June 22, 2026); data from EODHD.
PBM financial position
At the end of fiscal 2026 (March 31, 2026), Psyence Biomedical Ltd. had total assets of $17.6 million (up 140.1% from a year earlier), total liabilities of $0.6 million and shareholders' equity of $16.9 million. Its current ratio was 14.62.
Related: PBM income statement, PBM cash flow statement, PBM key metrics. See the PBM stock overview for the latest quote and news.
PBM balance sheet FAQ
What are Psyence Biomedical Ltd.'s total assets?
Psyence Biomedical Ltd. reported total assets of $17.6 million at the end of fiscal 2026 (March 31, 2026), compared with $7.3 million a year earlier.
How much cash does Psyence Biomedical Ltd. have?
Psyence Biomedical Ltd. held $7.4 million in cash and short-term investments at the end of fiscal 2026.
What is Psyence Biomedical Ltd.'s book value?
Psyence Biomedical Ltd.'s shareholders' equity (book value) was $16.9 million at the end of fiscal 2026.
What is Psyence Biomedical Ltd.'s current ratio?
Psyence Biomedical Ltd. had current assets of $9.1 million and current liabilities of $0.6 million, a current ratio of 14.62 (it can cover its short-term obligations).